Biotechnology stocks carry unique, elevated risks compared to traditional equity sectors, primarily due to their heavy reliance on clinical trial outcomes, regulatory approvals from agencies like the Food and Drug Administration, and patent protection timelines. A single negative clinical readout or a clinical hold can cause severe drops in share value. Additionally, early-stage biotech companies frequently experience continuous cash burn rates, lack immediate commercial revenue streams, and rely heavily on secondary share offerings or debt financing, exposing investors to significant stock dilution and high volatility.